The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
 
Shaji Kumar
Honoraria - BeiGene; Guangzhou Link Health Pharma; Secura Bio
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Amgen (Inst); Bluebird Bio (Inst); Celgene (Inst); Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Molecular Partners (Inst); Oncopeptides; Takeda (Inst)
Research Funding - Abbvie (Inst); CARsgen Therapeutics (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); TeneoBio (Inst)
 
Carlos R. Bachier
Employment - HCA Healthcare
 
Michele Cavo
Honoraria - Abbvie; Adaptive Biotechnologies; Amgen; Celgene/Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Mundipharma; Sanofi; Takeda
Speakers' Bureau - Celgene/Bristol-Myers Squibb; Janssen
 
Paolo Corradini
Honoraria - Abbvie; Amgen; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; KiowaKirin; Kite, a Gilead company; Novartis; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Celgene; Daiichi Sankyo; Gilead Sciences; Incyte; Janssen; Jazz Pharmaceuticals; KiowaKirin; Kite/Gilead; Nerviano Medical Sciences; Novartis; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - Abbvie; Celgene; Gilead Sciences; Janssen; Kite, a Gilead company; Novartis; Takeda
 
Michel Delforge
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Sanofi; Stemline Therapeutics; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Sanofi; Stemline Therapeutics; Takeda
 
Wojt Janowski
No Relationships to Disclose
 
Alexander M. Lesokhin
Honoraria - ITeos Therapeutics; Janssen; Legend Biotech; Pfizer; Sanofi; Trillium Therapeutics
Consulting or Advisory Role - Pfizer; Trillium Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst); Trillium Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Serametrix, Inc
 
Roberto Mina
No Relationships to Disclose
 
Laura Paris
No Relationships to Disclose
 
Laura Rosiñol
Honoraria - Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Sanofi
 
HANG QUACH
Consulting or Advisory Role - Amgen; Antengene; Bristol-Myers Squibb/Celgene; Celgene; CSL Behring; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Pfizer; Roche; Sanofi
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; Celgene; GlaxoSmithKline; Karyopharm Therapeutics; Sanofi
 
Grant R. Goodman
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Rin Nakamura
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Divya Samineni
Employment - Genentech
Stock and Other Ownership Interests - Genentech/Roche
 
Vallari Shah
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Elisabeth Wassner Fritsch
Employment - F. Hoffmann LaRoche
Stock and Other Ownership Interests - Roche
 
Jesus G. Berdeja
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); crispr therapeutics (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Legend Biotech (Inst); Roche (Inst); Secura Bio (Inst); Takeda (Inst)
Research Funding - 2Seventy bio (Inst); Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Amgen (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); CARsgen Therapeutics (Inst); Cartesian Therapeutics (Inst); Celgene (Inst); Celularity (Inst); crispr therapeutics (Inst); EMD Serono (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ichnos Sciences (Inst); Incyte (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); poseida therapeutics (Inst); Sanofi (Inst); Takeda (Inst); Teva (Inst)